

---

# Dissolution Testing and Specification Criteria for Immediate-Release Solid Oral Dosage Forms Containing Biopharmaceutics Classification System Class 1 and 3 Drugs Guidance for Industry

## ***DRAFT GUIDANCE***

**This guidance document is being distributed for comment purposes only.**

Comments and suggestions regarding this draft document should be submitted within 60 days of publication in the *Federal Register* of the notice announcing the availability of the draft guidance. Submit electronic comments to <http://www.regulations.gov>. Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number listed in the notice of availability that publishes in the *Federal Register*.

For questions regarding this draft document contact (CDER) Richard Lostritto at 301-796-1667.

**U.S. Department of Health and Human Services  
Food and Drug Administration  
Center for Drug Evaluation and Research (CDER)**

**August 2015  
Biopharmaceutics**

# Dissolution Testing and Specification Criteria for Immediate-Release Solid Oral Dosage Forms Containing Biopharmaceutics Classification System Class 1 and 3 Drugs Guidance for Industry

*Additional copies are available from:  
Office of Communications, Division of Drug Information  
Center for Drug Evaluation and Research  
Food and Drug Administration  
10001 New Hampshire Ave., Hillandale Bldg., 4<sup>th</sup> Floor  
Silver Spring, MD 20993-0002  
Phone: 855-543-3784 or 301-796-3400; Fax: 301-431-6353  
Email: [druginfo@fda.hhs.gov](mailto:druginfo@fda.hhs.gov)  
<http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm>*

**U.S. Department of Health and Human Services  
Food and Drug Administration  
Center for Drug Evaluation and Research (CDER)**

**August 2015  
Biopharmaceutics**

***Contains Nonbinding Recommendations***

*Draft — Not for Implementation*

**TABLE OF CONTENTS**

<b>I.</b>	<b>INTRODUCTION.....</b>	<b>1</b>
<b>II.</b>	<b>BACKGROUND .....</b>	<b>2</b>
<b>III.</b>	<b>ELIGIBLE PRODUCTS.....</b>	<b>3</b>
<b>A.</b>	<b>Dosage Form.....</b>	<b>3</b>
<b>B.</b>	<b>Solubility .....</b>	<b>3</b>
<b>C.</b>	<b>Therapeutic Class .....</b>	<b>3</b>
<b>D.</b>	<b>Time to Maximum Plasma Concentration.....</b>	<b>3</b>
<b>E.</b>	<b>Manufacturing and Testing History.....</b>	<b>4</b>
<b>F.</b>	<b>Excipients .....</b>	<b>4</b>
<b>IV.</b>	<b>STANDARD DISSOLUTION TEST CONDITIONS .....</b>	<b>4</b>
<b>A.</b>	<b>Basket Method (USP apparatus 1) .....</b>	<b>4</b>
<b>B.</b>	<b>Paddle Method (USP apparatus 2).....</b>	<b>4</b>
<b>V.</b>	<b>SPECIFICATION.....</b>	<b>5</b>
<b>VI.</b>	<b>REPLACING DISSOLUTION WITH DISINTEGRATION.....</b>	<b>5</b>
<b>VII.</b>	<b>REFERENCES.....</b>	<b>5</b>

**Dissolution Testing and Specification Criteria for Immediate-  
Release Solid Oral Dosage Forms Containing Biopharmaceutics  
Classification System Class 1 and 3 Drugs  
Guidance for Industry<sup>1</sup>**

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA or Agency) on this topic. It does not create any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the FDA staff responsible for this guidance as listed on the title page.

**I. INTRODUCTION**

This guidance is developed to provide manufacturers with recommendations for submission of new drug applications (NDAs), investigational new drug applications (INDs), and/or abbreviated new drug applications (ANDAs), as appropriate, for immediate-release (IR) tablets and capsules that contain highly soluble drug substances. The guidance is intended to describe when a standard release test and criteria may be used in lieu of extensive method development and specification-setting exercises. When final, this guidance will supersede the guidance for industry on [Dissolution Testing of Immediate Release Solid Oral Dosage Forms](#) (August 1997) for biopharmaceutics classification system (BCS) class 1 and 3 drug substances in immediate-release drug products that meet the criteria in this guidance.<sup>2</sup> For class 2 and 4 drug substances, applicants should still refer to the August 1997 guidance mentioned above.

In general, FDA's guidance documents do not establish legally enforceable responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word *should* in Agency guidances means that something is suggested or recommended, but not required.

<sup>1</sup> This guidance has been prepared by the Dissolution Technical Advisory Group (TAG) team in the Center for Drug Evaluation and Research (CDER) at the Food and Drug Administration.

<sup>2</sup> We update guidances periodically. To make sure you have the most recent version of a guidance, check the FDA Drugs guidance Web page at <http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm>.

## **II. BACKGROUND**

Drug absorption from a solid dosage form after oral administration depends on the release of the drug substance from the drug product, the dissolution or solubilization of the drug under physiological conditions, and the permeation across the gastrointestinal membrane.<sup>3</sup> NDAs and ANDAs submitted to FDA contain bioavailability (BA) or bioequivalence (BE) data and in vitro dissolution data that, together with chemistry, manufacturing, and controls (CMC) data, characterize the quality and performance of the drug product. In vitro dissolution data are generally obtained from batches that have been used in pivotal clinical and/or bioavailability/bioequivalence studies, and from other human studies conducted during product development. Knowledge about the solubility, permeability, dissolution, and pharmacokinetics of a drug product is considered when defining dissolution test specifications for the drug approval process.

The BCS is a scientific framework for classifying drug substances based on their aqueous solubility and intestinal permeability. The definitions of high and low solubility and high and low permeability are used as described in the Biopharmaceutics Classification System (BCS) Guidance.<sup>4</sup> The different classifications are:

- Class 1: High Solubility - High Permeability Drugs
- Class 2: Low Solubility - High Permeability Drugs
- Class 3: High Solubility - Low Permeability Drugs
- Class 4: Low Solubility - Low Permeability Drugs

This classification can be used as a basis for determining when in vivo BA and BE studies are needed and can be used to determine when a successful in vitro-in vivo correlation (IVIVC) is likely. The BCS suggests that, for certain high solubility drugs, dissolution testing can be standardized. Owing to their high solubility, BCS class 1 and 3 drugs are considered to be relatively low risk regarding the impact of dissolution on performance, provided the in vitro performance meets or exceeds the recommendations discussed herein.

This guidance establishes standard dissolution methodology and specifications that are appropriate for BCS class 1 and class 3 drugs in IR dosage form. The availability of these standards will facilitate the rapid development of dissolution methodology and related specifications for these classes during drug development and application review.

---

<sup>3</sup> Amidon GL, Lennernas H, Shah VP, and Crison JR, 1995, A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of In Vitro Drug Product Dissolution and In Vivo Bioavailability, *Pharm. Res.*, 12:413-420.

<sup>4</sup> See <http://www.fda.gov/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/ucm128219.htm> and guidance for industry on *Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System* (May 2015), available at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070246.pdf>.

## ***Contains Nonbinding Recommendations***

*Draft — Not for Implementation*

### **III. ELIGIBLE PRODUCTS**

In addition to being an IR dosage form, your drug product should meet all of the following conditions in order for the dissolution standards in this guidance to apply.<sup>5</sup> You also should follow Agency guidances to establish that your drug product is either a BCS class 1 or 3 product.<sup>6</sup> To help determine if your product meets any particular condition listed below, contact the review division for your specific drug product.

#### **A. Dosage Form**

This guidance applies to solid orally-administered immediate release dosage forms, such as tablets and capsules that are meant to be swallowed. It does not include chewable tablets, and does not apply to orally disintegrating tablets.

#### **B. Solubility**

To be considered BCS class 1 or 3,<sup>7</sup> the drug substance should be considered highly soluble with the highest dose strength soluble in 250 mL or less of aqueous media over the pH range of 1 to 6.8.<sup>8</sup> The drug substance should also be chemically stable for 24 hours over this same pH range.

#### **C. Therapeutic Class**

This guidance does not apply to narrow therapeutic index (NTI) drugs because of the critical relationship between the bioavailable dose (and therefore dissolution) on clinical performance. For more information on NTI drugs, the current approach to establish the NTI classification of a drug is described in the draft product-specific guidance on Warfarin Sodium, posted December 2012, on the FDA Web site for Individual Product Bioequivalence Recommendations, <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM201283.pdf>.

#### **D. Time to Maximum Plasma Concentration**

If the time to maximum plasma concentration is critical to the intended use, this guidance does not apply. For example, labeling claims of early or rapid onset of action (e.g., rapid analgesia, rescue medications, etc.) exclude the product from adoption of the dissolution standards proposed herein.

---

<sup>5</sup> For these classes of products, these recommendations will supersede those in the Dissolution Methods Database, and upon finalization of this guidance FDA will update the Dissolution Methods Database or remove entries from the Database that are covered by this guidance. For products where the method described in a United States Pharmacopeia (USP) drug product monograph differs from the recommendations of this guidance, ANDA applicants may propose to use the approaches in this guidance as an alternative method and seek revision of the relevant monograph.

<sup>6</sup> *Supra* note 5.

<sup>7</sup> *Supra* note 5.

<sup>8</sup> For ANDAs, the highest dose strength for which approval is sought.

## ***Contains Nonbinding Recommendations***

*Draft — Not for Implementation*

### **E. Manufacturing and Testing History**

Manufacturing and testing history, including stability testing, should demonstrate that the product will meet the specifications in this guidance when using the standard dissolution test conditions.

### **F. Excipients**

Excipients chosen for drug product formulations should be consistent with the design of IR drug products. Excipients should be included in normal quantities that are consistent with the product's labeled function. Large quantities of excipients, such as sweeteners and surfactants, may be problematic. You are encouraged to contact the review division for your specific drug product when this is a factor.

## **IV. STANDARD DISSOLUTION TEST CONDITIONS**

If a product is deemed to be eligible for a standard dissolution method and specification, you should use one of the following methods.<sup>9</sup> Information on apparatus and number of units to test can be found in the USP General Chapter <711> Dissolution. You should calibrate apparatus before use.<sup>10</sup>

### **A. Basket Method (USP apparatus 1)**

- Stirring rate = 100 RPM
- 500 mL of 0.01M HCl aqueous media
- No surfactant in media
- 37±0.5°C

### **B. Paddle Method (USP apparatus 2)**

- Stirring rate = 75 RPM
- 500 mL of 0.01M HCl aqueous media
- No surfactant in media
- 37±0.5°C

Although the hydrodynamics of the gastrointestinal tract are complicated and cannot be reproduced by the USP basket or paddle apparatus, a stirring rate of 100 RPM has been found to be discriminatory for the basket method. For the paddle method, 75 RPM can be discriminatory while minimizing coning effects seen with lower rates. The acid conditions of the media reflect the conditions of the stomach whose volume is estimated at 250 mL when a glass of water is co-

<sup>9</sup> Shah V, Gurbarg M, Noory A, Dighe S, Skelly J, 1992, Influence of higher rates of agitation on release patterns of IR drug products, J Pharm Sci 81(6) 500-503.

<sup>10</sup> See guidance for industry on *The Use of Mechanical Calibration of Dissolution Apparatus 1 and 2 – Current Good Manufacturing Practice (CGMP)* (January 2010), available at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM198649.pdf>.

## ***Contains Nonbinding Recommendations***

*Draft — Not for Implementation*

146 ingested with the oral dosage form. This volume is too low to use with the current basket and  
147 paddle apparatus; however, 500 mL of media is commonly used and should be a sufficient  
148 volume of media for a highly soluble, rapidly dissolving drug.

### **V. SPECIFICATION**

151  
152 The drug product dissolution specification will depend on the BCS class of the drug substance and  
153 should follow the recommendations below. Applicants may consider further supporting their  
154 proposed dissolution specifications with appropriate simulations in addition to dissolution  
155 performance data.

- 156  
157 • For BCS class 1 products, a single point dissolution specification of Q=80% in 30 minutes.
- 158  
159 • For BCS class 3 products, a single point dissolution specification of Q=80% in 15 minutes.

160  
161 BCS class 3 products that meet the more stringent specifications will better ensure that the  
162 bioavailability of the drug is not limited by dissolution, and the rate-limiting step for drug  
163 absorption becomes gastric emptying. For ANDAs, these criteria should apply unless supported  
164 by data on the dissolution performance of the reference-listed drug.

### **VI. REPLACING DISSOLUTION WITH DISINTEGRATION**

165  
166  
167  
168 For drug products in both BCS classes 1 and 3, USP disintegration testing can be used in lieu of the  
169 dissolution test if the product is shown to meet a dissolution specification of Q=80% in 15 minutes.

170  
171 For drug products that meet this criterion, the USP disintegration test, which requires the product  
172 to completely disintegrate within 5 minutes (via USP apparatus in 0.01M HCl), may serve as a  
173 surrogate for routine release and stability dissolution testing. However, the approved dissolution  
174 method should be retained as the primary method and the approved disintegration method as an  
175 alternate method. Note that to support post-approval changes for which dissolution testing would  
176 be typically be needed, you should use the approved dissolution method.

### **VII. REFERENCES**

177  
178  
179  
180 Amidon GL, Lennernas H, Shah VP, and Crison JR, 1995, A Theoretical Basis for a  
181 Biopharmaceutic Drug Classification: The Correlation of In Vitro Drug Product Dissolution and  
182 In Vivo Bioavailability, Pharm Res, 12:413-420.

183  
184 Dickinson PA, et al., 2008, Clinical Relevance of Dissolution Testing in Quality by Design,  
185 AAPS Journal, Vol. 10, No. 2.

186  
187 FDA guidance for industry, 1995, Immediate Release Solid Oral Dosage Forms. Scale-up and  
188 Post-Approval Changes: Chemistry, Manufacturing, and Controls, In Vitro Dissolution Testing,  
189 and In Vivo Bioequivalence Documentation [SUPAC-IR].



## ***Contains Nonbinding Recommendations***

*Draft — Not for Implementation*

191 FDA guidance for industry, 1997, Dissolution Testing of Immediate Release Solid Oral Dosage  
192 Forms.  
193  
194 FDA guidance for industry, 2010, The Use of Mechanical Calibration of Dissolution Apparatus 1  
195 and 2 – Current Good Manufacturing Practice (CGMP).  
196  
197 FDA guidance for industry, 2000, Waiver of In Vivo Bioavailability and Bioequivalence Studies  
198 for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification  
199 System.  
200  
201 FDA guidance for industry, 2015, Waiver of In Vivo Bioavailability and Bioequivalence Studies  
202 for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification  
203 System.  
204  
205 FDA draft guidance for industry, 2012, Warfarin Sodium.  
206  
207 Shah V, Gurbarg M, Noory A, Dighe S, Skelly J, 1992, Influence of higher rates of agitation on  
208 release patterns of IR drug products, J Pharm Sci 81(6) 500-503.  
209  
210 Strauch S, Jantratid E, and Dressman JB, 2009, Comparison of WHO and US FDA biowaivers  
211 dissolution test conditions using bioequivalent doxycycline hyclate drug products, J Pharmacy  
212 and Pharmacology, 61:331-337.  
213  
214 United States Pharmacopeia (USP) General Chapters <711> Dissolution (2011), <701>  
215 Disintegration (2008).  
216  
217 WHO,, 2006, Proposal to waive in vivo bioequivalence requirements for WHO Model List of  
218 Essential Medicines immediate-release, solid oral dosage forms. Annex 8 of WHO Expert  
219 Committee on Specifications for Pharmaceutical Preparations. Geneva: WHO.  
220  
221 Yu LX, et al., 2002, BCS: The Scientific Basis of Biowaiver Extensions, Pharm Research, 19(7)  
222 921-925.  
223  
224